Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Antiviral Res. 2015 Sep 25;123:114–119. doi: 10.1016/j.antiviral.2015.09.008

Table 2.

Demographics

DAS181-F03 DAS181-F04 DAS181-F03 Placebo
1-Day Cohort 3-Day Cohort 10-Day Cohort Combined Cohorts
N = 6 N = 6 N = 6 N = 9
Mean Age (yr) 42a 32 30 29
Gender-Male, # (%) 6 (100%) 3 (50%) 1b (17%) 7 (78%)
Race, # (%)
 African American 5 (83%) 4 (67%) 2 (33%) 3 (33%)
 Caucasian 0 2 (33%) 4 (67%) 4 (44%)
 Asian 0 0 0 2 (22%)
 Other 1 (17%) 0 0 0
Ethnicity, # (%)
 Hispanic or Latino 0 1 (17%) 1 (17%) 1 (11%)
 Non-Hispanic or Latino 6 (100%) 5 (83%) 5 (83%) 8 (89%)
a

The mean age of the 1-day cohort was greater than the mean age of the placebo group (p=0.002)

b

The % men in the 10-day cohort was less than in the placebo group (p=0.04)